Compare DexCom, Inc. (DXCM) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs SPDR Kensho Final Frontiers ETF — how do they compare? DexCom, Inc. trades at $83.92 (market cap $31.86B), while SPDR Kensho Final Frontiers ETF trades at $102.69 (market cap $170.14M). The key difference: DexCom, Inc. is far larger — about 187.3× SPDR Kensho Final Frontiers ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, SPDR Kensho Final Frontiers ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and SPDR Kensho Final Frontiers ETF for 8 Days on average.
| DXCM | ROKT | |
|---|---|---|
Market Cap | $31.86B | $170.14M |
Volume | 3,607,070 | 12,298 |
Sector | Health | Sector/Thematic |
52-Week High | $92.34 | $136.68 |
52-Week Low | $54.84 | $72.93 |
Typical Hold Time | 62 Days | 8 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
